Chronic obstructive pulmonary disease is a frequent medical condition, mainly triggered by smoking. COPD patients often suffer from heart diseases that can benefit from beta-blocker therapy. However, fear from triggering latent bronchospasm, or from worsening it, leads to under-prescription of these agents. Adequate patient selection is, thus, crucial. Prescription of a cardio-selective beta-blocker is not only reasonably safe in stable COPD patients but it is also beneficial in terms of mortality in those patients with comorbid cardiac diseases. Use of beta-blockers is contra-indicated in the case of decompensated COPD with severe bronchospasm or in poorly controlled asthma. In all cases, close clinical and, sometimes, functional monitoring is mandatory.